Volume 94 Issue 36 | p. 15 | Concentrates
Issue Date: September 12, 2016

Allergan buys gene therapy firm

Department: Business
Keywords: mergers & acquisitions, biotech, gene therapy, ophthalmology

Allergan will pay $60 million up front to acquire RetroSense Therapeutics, which is developing gene therapies to restore sight in people with eye diseases. With the deal, Allergan gains access to RST-001, a gene therapy being tested in a Phase I/II study against retinitis pigmentosa, a rare disease marked by peripheral vision loss, night vision challenges, and eventual blindness. RST-001 delivers a gene called channelrhodopsin-2 that may allow new photosensors to be created in retinal ganglion cells.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment